Re: Losing ground in delays
|
6
|
Resverlogix Corp.
|
Jul 08, 2024 09:12AM
|
Re: While we wait…
|
11
|
Resverlogix Corp.
|
Jun 14, 2024 05:30PM
|
Re: Long covid trials
|
7
|
Resverlogix Corp.
|
Aug 03, 2023 09:01PM
|
Re: Long covid trials
|
1
|
Resverlogix Corp.
|
Aug 03, 2023 08:56PM
|
Re: Long covid trials
|
7
|
Resverlogix Corp.
|
Aug 02, 2023 06:57PM
|
Long covid trials
|
9
|
Resverlogix Corp.
|
Jul 31, 2023 07:03PM
|
Re: While we fiddle
|
7
|
Resverlogix Corp.
|
Jul 21, 2023 06:41PM
|
Previous message
|
1
|
Resverlogix Corp.
|
Jun 13, 2023 07:34PM
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
4
|
Resverlogix Corp.
|
Jun 13, 2023 07:25PM
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
7
|
Resverlogix Corp.
|
Jun 13, 2023 07:24PM
|
Re: AGM
|
5
|
Resverlogix Corp.
|
Jun 06, 2023 08:03PM
|
Re: Another Report of Exempt Distribution
|
6
|
Resverlogix Corp.
|
Mar 20, 2023 09:43AM
|
New paper
|
7
|
Resverlogix Corp.
|
Mar 19, 2023 08:04AM
|
Re: China- 1 Million daily COVID cases
|
4
|
Resverlogix Corp.
|
Dec 31, 2022 06:42PM
|
Re: Update from IR -- Eversana paused?
|
5
|
Resverlogix Corp.
|
Dec 20, 2022 12:50AM
|
Re: Thrown in the towel?
|
8
|
Resverlogix Corp.
|
Aug 01, 2022 04:04PM
|
Re: Article
|
9
|
Resverlogix Corp.
|
May 29, 2022 04:26PM
|
Re: Study results?
|
2
|
Resverlogix Corp.
|
Mar 07, 2022 07:30PM
|
Re: Study results?
|
14
|
Resverlogix Corp.
|
Mar 06, 2022 06:17PM
|
Re: Epigenetics
|
10
|
Resverlogix Corp.
|
Feb 13, 2022 05:48PM
|